First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE
First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program
Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis.
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
